Mitochondrial uncoupling protein 2 regulates the effects of paclitaxel on Stat3 activation and cellular survival in lung cancer cells

Carcinogenesis

Volumn 33, Issue 11, 2012, Pages 2065-2075

  Su, Wen Pin ^a,b   Lo Ya Chin, C ^a   Yan, Jin Jou ^b   Liao, I Chuang ^b   Tsai, Pei Jane ^a   Wang, Hao Chen ^a   Yeh, Hsuan Heng ^b   Lin, Chien Chung ^b   Chen, Helen H W ^b   Lai, Wu Wei ^b   Su, Wu Chou ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; CISPLATIN; COMPLEMENTARY DNA; JANUS KINASE 2; PACLITAXEL; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; ROTENONE; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; SURVIVIN; UNCOUPLING PROTEIN 2;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; INOPERABLE CANCER; LUNG CANCER; MITOCHONDRIAL MEMBRANE; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CISPLATIN; HUMANS; IMMUNOENZYME TECHNIQUES; ION CHANNELS; LUNG; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; PACLITAXEL; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SURVIVAL RATE;

EID: 84868621199     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs253     Document Type: Article

References (50)

1. Janku, F. et al. (2010) Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat. Rev. Clin. Oncol., 7, 401-414.
2. Winograd-Katz, S.E. et al. (2006) Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene, 25, 7381-7390.
3. Collins, T.S. et al. (2000) Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism. Cancer Immunol. Immunother., 49, 78-84.
4. Jing, N. et al. (2005) Targeting Stat3 in cancer therapy. Anticancer. Drugs, 16, 601-607.
5. Gritsko, T. et al. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res., 12, 11-19.
6. Wegrzyn, J. et al. (2009) Function of mitochondrial Stat3 in cellular respiration. Science, 323, 793-797.
7. Song, L. et al. (2003) Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene, 22, 4150-4165.
8. Ikuta, K. et al. (2005) Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. Oncol. Rep., 13, 217-222.
9. Walker, S.R. et al. (2010) Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol. Pharmacol., 78, 903-908.
10. Pelicano, H. et al. (2004) ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat., 7, 97-110.
11. Alexandre, J. et al. (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int. J. Cancer, 119, 41-48.
12. Fruehauf, J.P. et al. (2007) Reactive oxygen species: a breath of life or death? Clin. Cancer Res., 13, 789-794.
13. Simon, A.R. et al. (1998) Activation of the JAK-STAT pathway by reactive oxygen species. Am. J. Physiol., 275(6 Pt 1), C1640-C1652.
14. Wang, J. et al. (2008) Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol. Ther., 7, 1875-1884.
15. Kim, H.S. et al. (2008) Paclitaxel induces vascular endothelial growth factor expression through reactive oxygen species production. Pharmacology, 81, 317-324.
16. Baffy, G. (2010) Uncoupling protein-2 and cancer. Mitochondrion, 10, 243-252.
17. Derdák, Z. et al. (2006) Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. Carcinogenesis, 27, 956-961.
18. Horimoto, M. et al. (2004) Expression of uncoupling protein-2 in human colon cancer. Clin. Cancer Res., 10(18 Pt 1), 6203-6207.
19. Collins, P. et al. (2005) Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis. Liver Int., 25, 880-887.
20. Derdak, Z. et al. (2008) The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res., 68, 2813-2819.
21. Basu Ball, W. et al. (2011) Uncoupling protein 2 negatively regulates mitochondrial reactive oxygen species generation and induces phosphatase-mediated anti-inflammatory response in experimental visceral leishmaniasis. J. Immunol., 187, 1322-1332.
22. Samudio, I. et al. (2008) The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res., 68, 5198-5205.
23. Yeh, H.H. et al. (2006) Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene, 25, 4300-4309.
24. Chen, J.J. et al. (2001) Global analysis of gene expression in invasion by a lung cancer model. Cancer Res., 61, 5223-5230.
25. Alley, M.C. et al. (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48, 589-601.
26. Boiadjieva, S. et al. (1984) Methods in laboratory investigation. Exclusion of trypan blue from microcarriers by endothelial cells: an in vitro barrier function test. Lab. Invest., 50, 239-246.
27. Chang, C.W. et al. (2009) The IL-8 production by Streptococcal pyrogenic exotoxin B. Exp. Biol. Med. (Maywood), 234, 1316-1326.
28. Liu, T. et al. (2007) Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol. Cancer Ther., 6, 1814-1822.
29. Manfredi, G. et al. (2002) Measurements of ATP in mammalian cells. Methods, 26, 317-326.
30. Therasse, P. et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst., 92, 205-216.
31. Decker, T. et al. (2000) Serine phosphorylation of STATs. Oncogene, 19, 2628-2637.
32. Selimovic, D. et al. (2008) Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2. Cell. Signal., 20, 311-322.
33. Li, Y. et al. (1998) Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem. Biophys. Res. Commun., 253, 295-299.
34. Liu, B. et al. (2000) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J. Pharmacol. Exp. Ther., 293, 607-617.
35. Ling, X. et al. (2004) Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J. Biol. Chem., 279, 15196-15203.
36. Liu, H. et al. (2011) B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol. Cancer Ther., 10, 960-971.
37. Kubo, M. et al. (2003) Suppressors of cytokine signaling and immunity. Nat. Immunol., 4, 1169-1176.
38. Piñeiro, D. et al. (2007) Calpain inhibition stimulates caspase-dependent apoptosis induced by taxol in NIH3T3 cells. Exp. Cell Res., 313, 369-379.
39. Grivennikov, S.I. et al. (2010) Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev., 21, 11-19.
40. Martindale, J.L. et al. (2002) Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol., 192, 1-15.
41. Soussi, T. (2003) p53 mutations and resistance to chemotherapy: A stab in the back for p73. Cancer Cell, 3, 303-305.
42. Masuda, A. et al. (2003) Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am. J. Pathol., 163, 1109-1116.
43. Brosh, R. et al. (2009) When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer, 9, 701-713.
44. You, L. et al. (2000) ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res., 60, 1009-1013.
45. Wang, Y.F. et al. (2004) Involvement of oxidative stress and caspase activation in paclitaxel-induced apoptosis of primary effusion lymphoma cells. Cancer Chemother. Pharmacol., 54, 322-330.
46. Alexandre, J. et al. (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res., 67, 3512-3517.
47. Li, Z.Y. et al. (2011) Mitochondrial ROS generation for regulation of autophagic pathways in cancer. Biochem. Biophys. Res. Commun., 414, 5-8.
48. Ajabnoor, G.M. et al. (2012) Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis., 3, e260.
49. Sayeed, A. et al. (2010) Negative regulation of UCP2 by TGFß signaling characterizes low and intermediate-grade primary breast cancer. Cell Death Dis., 1, e53.
50. Ohkouchi, S. et al. (2012) Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1. Mol. Ther., 20, 417-423.